Ipsc-Mnp
ALS
Shanghai East HospitalCell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
150 Active assets in the ALS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAURURSODIOL Amylyx Pharmaceuticals Inc. | Phase 3 | BBB |
Tofersen Biogen | Phase 4 | BBB |
Riluzole AB Science | Phase 4 | BB |
Mexiletine Bjorn Oskarsson, MD | Phase 4 | BB |
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II) Collaborative Medicinal Development Pty Limited | Phase 2/3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →